妊娠期启动抗逆转录病毒治疗的HIV感染女性病毒血症发作频率:一项队列研究
南非开普敦523名妊娠期启动ART并达到病毒抑制的HIV感染女性被随访至产后12个月,70%维持病毒抑制,22%至少出现一次主要病毒血症发作,产后及年轻、孕晚期启动ART、既往脱失与主要病毒血症发作独立相关。
要点
- 妊娠期启动ART并达到病毒抑制后,22%女性至少出现一次主要病毒血症发作。
- 产后随访与主要病毒血症发作独立相关,需加强产后病毒载量监测。
- 年轻、孕晚期启动ART、既往脱失ART也是主要病毒血症发作的独立相关因素。
核心结论
- 在该研究环境中,HIV感染女性妊娠期启动ART并初始达到病毒抑制后,病毒血症发作频繁,尤其产后。
- 需要对该人群进行更密集的病毒载量监测,病毒血症发作的直接原因和长期影响有待研究。
研究设计与样本
- 前瞻性队列研究,纳入南非开普敦523名妊娠期启动ART(替诺福韦300 mg、恩曲他滨200 mg、依非韦伦600 mg每日一次)并达到病毒抑制(<50拷贝/mL)的HIV感染女性。
- 参与者通过产后12个月提供标本进行批量病毒载量检测,独立于常规护理。
- 分析主要病毒血症发作(>1000拷贝/mL)和次要病毒血症发作(50-1000拷贝/mL)的发生率及与主要发作相关的因素。
主要发现
- 队列中位年龄28岁,中位ART前病毒载量3.99拷贝/mL,3%既往脱失ART,24%既往暴露于短程抗逆转录病毒药物。
- 从病毒抑制起中位随访时间322天。
- 总体70%维持病毒抑制,8%仅出现次要病毒血症发作,22%女性至少记录到一次主要病毒血症发作。
- 出现病毒血症发作的女性中,峰值病毒血症(中位3.79 log10拷贝/mL)与ART前病毒载量呈线性相关。
- 初始病毒抑制后主要病毒血症发作的发生率与较年轻年龄、孕晚期启动ART、既往脱失ART和产后随访独立相关。
临床怎么用
- 对妊娠期启动ART的HIV感染女性,尤其产后、年轻、孕晚期启动ART或既往脱失者,应考虑更密集的病毒载量监测。
局限性
- 病毒血症发作的直接原因和长期影响尚未明确,需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The numbers of human immunodeficiency virus (HIV)-infected women initiating antiretroviral therapy (ART) in pregnancy are increasing rapidly with global policy changes. There are widespread concerns about ART adherence during pregnancy and postpartum but few data on viral suppression (VS) over time in these populations. METHODS: We followed a cohort of 523 women in Cape Town, South Africa, initiating ART in pregnancy (once-daily tenofovir 300 mg, emtricitabine 200 mg, and efavirenz 600 mg) and achieving VS (<50 copies/mL). Participants provided specimens through 12 months postpartum for batched viral load (VL) testing separate from routine care. Analyses described the incidence of major (>1000 copies/mL) and minor (50-1000 copies/mL) viremic episodes (VEs) and factors associated with major VEs. RESULTS: In the cohort (median age, 28 years; median pre-ART VL, 3.99 copies/mL; 3% previously defaulted ART; 24% with previous exposure to short-course antiretrovirals), the median time of follow-up from VS was 322 days. Overall, 70% maintained VS throughout follow-up, 8% experienced minor VEs only, and at least 1 major VE was documented in 22% of women. In women with VEs, peak viremia (median, 3.79 log10 copies/mL) was linearly related to pre-ART VL. The incidence of major VEs after initial VS was independently associated with younger age, ART initiation during the third trimester, previous defaulting on ART, and postpartum follow-up. CONCLUSIONS: Viremia appears to occur frequently, particularly postpartum, among HIV-infected women after initial VS in this setting. More intensive VL monitoring is warranted in this population; the immediate causes and long-term implications of VE require investigation.
引用
- Myer L, Dunning L, Lesosky M, et al. Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study. Clin Infect Dis. 2017. PMID: 27927852. doi:10.1093/cid/ciw792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。